The role of statins in diabetes treatment

Bishnu H. Subedi, Rajesh Tota-Maharaj, Michael G. Silverman, C. Michael Minder, Seth Martin, M. Dominique Ashen, Roger S Blumenthal, Michael Blaha

Research output: Contribution to journalArticle

Abstract

Diabetes is considered a risk equivalent for coronary heart disease (CHD). The use of statins for primary and secondary prevention in patients with diabetes is well established and supported by robust data from randomized, controlled trials and national guidelines. The American Diabetes Association recommends that individuals with diabetes and a history of cardiovascular disease (CVD), as well as those > 40 years of age without CVD but with CVD risk factors, should be treated with a statin regardless of their baseline LDL cholesterol concentration. This review explains the rationale behind considering diabetes a CHD risk equivalent and summarizes the data for statin use in adults with diabetes without (primary prevention) and with (secondary prevention) established CVD. Although individuals with diabetes are at an increased risk for CVD and benefit from statin therapy, the risk of CVD in people with diabetes is heterogeneous. It therefore may be reasonable to match the intensity of statin therapy with patients' baseline CVD risk.

Original languageEnglish (US)
Pages (from-to)156-164
Number of pages9
JournalDiabetes Spectrum
Volume26
Issue number3
DOIs
StatePublished - Aug 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiovascular Diseases
Primary Prevention
Secondary Prevention
Therapeutics
Coronary Disease
LDL Cholesterol
Randomized Controlled Trials
Guidelines

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Subedi, B. H., Tota-Maharaj, R., Silverman, M. G., Minder, C. M., Martin, S., Ashen, M. D., ... Blaha, M. (2013). The role of statins in diabetes treatment. Diabetes Spectrum, 26(3), 156-164. https://doi.org/10.2337/diaspect.26.3.156

The role of statins in diabetes treatment. / Subedi, Bishnu H.; Tota-Maharaj, Rajesh; Silverman, Michael G.; Minder, C. Michael; Martin, Seth; Ashen, M. Dominique; Blumenthal, Roger S; Blaha, Michael.

In: Diabetes Spectrum, Vol. 26, No. 3, 08.2013, p. 156-164.

Research output: Contribution to journalArticle

Subedi, BH, Tota-Maharaj, R, Silverman, MG, Minder, CM, Martin, S, Ashen, MD, Blumenthal, RS & Blaha, M 2013, 'The role of statins in diabetes treatment', Diabetes Spectrum, vol. 26, no. 3, pp. 156-164. https://doi.org/10.2337/diaspect.26.3.156
Subedi BH, Tota-Maharaj R, Silverman MG, Minder CM, Martin S, Ashen MD et al. The role of statins in diabetes treatment. Diabetes Spectrum. 2013 Aug;26(3):156-164. https://doi.org/10.2337/diaspect.26.3.156
Subedi, Bishnu H. ; Tota-Maharaj, Rajesh ; Silverman, Michael G. ; Minder, C. Michael ; Martin, Seth ; Ashen, M. Dominique ; Blumenthal, Roger S ; Blaha, Michael. / The role of statins in diabetes treatment. In: Diabetes Spectrum. 2013 ; Vol. 26, No. 3. pp. 156-164.
@article{4b7017a975ba4b5086b5bf0f46924982,
title = "The role of statins in diabetes treatment",
abstract = "Diabetes is considered a risk equivalent for coronary heart disease (CHD). The use of statins for primary and secondary prevention in patients with diabetes is well established and supported by robust data from randomized, controlled trials and national guidelines. The American Diabetes Association recommends that individuals with diabetes and a history of cardiovascular disease (CVD), as well as those > 40 years of age without CVD but with CVD risk factors, should be treated with a statin regardless of their baseline LDL cholesterol concentration. This review explains the rationale behind considering diabetes a CHD risk equivalent and summarizes the data for statin use in adults with diabetes without (primary prevention) and with (secondary prevention) established CVD. Although individuals with diabetes are at an increased risk for CVD and benefit from statin therapy, the risk of CVD in people with diabetes is heterogeneous. It therefore may be reasonable to match the intensity of statin therapy with patients' baseline CVD risk.",
author = "Subedi, {Bishnu H.} and Rajesh Tota-Maharaj and Silverman, {Michael G.} and Minder, {C. Michael} and Seth Martin and Ashen, {M. Dominique} and Blumenthal, {Roger S} and Michael Blaha",
year = "2013",
month = "8",
doi = "10.2337/diaspect.26.3.156",
language = "English (US)",
volume = "26",
pages = "156--164",
journal = "Diabetes Spectrum",
issn = "1040-9165",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - The role of statins in diabetes treatment

AU - Subedi, Bishnu H.

AU - Tota-Maharaj, Rajesh

AU - Silverman, Michael G.

AU - Minder, C. Michael

AU - Martin, Seth

AU - Ashen, M. Dominique

AU - Blumenthal, Roger S

AU - Blaha, Michael

PY - 2013/8

Y1 - 2013/8

N2 - Diabetes is considered a risk equivalent for coronary heart disease (CHD). The use of statins for primary and secondary prevention in patients with diabetes is well established and supported by robust data from randomized, controlled trials and national guidelines. The American Diabetes Association recommends that individuals with diabetes and a history of cardiovascular disease (CVD), as well as those > 40 years of age without CVD but with CVD risk factors, should be treated with a statin regardless of their baseline LDL cholesterol concentration. This review explains the rationale behind considering diabetes a CHD risk equivalent and summarizes the data for statin use in adults with diabetes without (primary prevention) and with (secondary prevention) established CVD. Although individuals with diabetes are at an increased risk for CVD and benefit from statin therapy, the risk of CVD in people with diabetes is heterogeneous. It therefore may be reasonable to match the intensity of statin therapy with patients' baseline CVD risk.

AB - Diabetes is considered a risk equivalent for coronary heart disease (CHD). The use of statins for primary and secondary prevention in patients with diabetes is well established and supported by robust data from randomized, controlled trials and national guidelines. The American Diabetes Association recommends that individuals with diabetes and a history of cardiovascular disease (CVD), as well as those > 40 years of age without CVD but with CVD risk factors, should be treated with a statin regardless of their baseline LDL cholesterol concentration. This review explains the rationale behind considering diabetes a CHD risk equivalent and summarizes the data for statin use in adults with diabetes without (primary prevention) and with (secondary prevention) established CVD. Although individuals with diabetes are at an increased risk for CVD and benefit from statin therapy, the risk of CVD in people with diabetes is heterogeneous. It therefore may be reasonable to match the intensity of statin therapy with patients' baseline CVD risk.

UR - http://www.scopus.com/inward/record.url?scp=84892638327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892638327&partnerID=8YFLogxK

U2 - 10.2337/diaspect.26.3.156

DO - 10.2337/diaspect.26.3.156

M3 - Article

VL - 26

SP - 156

EP - 164

JO - Diabetes Spectrum

JF - Diabetes Spectrum

SN - 1040-9165

IS - 3

ER -